FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory ped...
Рет қаралды 5,240
Күн бұрынListen to a soundcast of the April 23, 2024, FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
U.S. Food and Drug Administration
Рет қаралды 1,3 М.
U.S. Food and Drug Administration
Рет қаралды 2,4 М.
U.S. Food and Drug Administration
Рет қаралды 8 М.
U.S. Food and Drug Administration
Рет қаралды 1,5 М.
U.S. Food and Drug Administration
Рет қаралды 4,4 М.
FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory...
U.S. Food and Drug Administration
Рет қаралды 273
U.S. Food and Drug Administration
Рет қаралды 776
U.S. Food and Drug Administration
Рет қаралды 463
FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adul...
U.S. Food and Drug Administration
Рет қаралды 327
U.S. Food and Drug Administration
Рет қаралды 519
U.S. Food and Drug Administration
Рет қаралды 8 М.